[go: up one dir, main page]

MX2019003888A - Compuestos de briostatina y metodos para prepararlos. - Google Patents

Compuestos de briostatina y metodos para prepararlos.

Info

Publication number
MX2019003888A
MX2019003888A MX2019003888A MX2019003888A MX2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A MX 2019003888 A MX2019003888 A MX 2019003888A
Authority
MX
Mexico
Prior art keywords
methods
bryostatin
preparing
same
variety
Prior art date
Application number
MX2019003888A
Other languages
English (en)
Inventor
Wender Paul
Quiroz Ryan
Ho Stephen
Ryckbosch Steven
C Stevens Matthew
S Jeffreys Matthew
HARDMAN Clayton
Sloane Jack
Shimizu Akira
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2019003888A publication Critical patent/MX2019003888A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan métodos para preparar una variedad de compuestos de briostatina. Los métodos de la presente proporcionan la preparación de briostatina 1 en cantidades de múltiples gramos en una cantidad baja y sin precedentes de etapas sintéticas convergentes a partir de materiales disponibles en el mercado. Los métodos de la presente son escalables con bajos costos de materiales estimados y pueden proporcionar una cantidad suficiente de material para satisfacer los requisitos clínicos. También se proporciona una variedad de compuestos análogos de briostatina, y formas de profármaco de estos, a los que puede accederse de manera sintética a través de los métodos de la presente y composiciones farmacéuticas que los incluyen.
MX2019003888A 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos. MX2019003888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404687P 2016-10-05 2016-10-05
PCT/US2017/054158 WO2018067382A1 (en) 2016-10-05 2017-09-28 Bryostatin compounds and methods of preparing the same

Publications (1)

Publication Number Publication Date
MX2019003888A true MX2019003888A (es) 2019-11-28

Family

ID=61831583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003888A MX2019003888A (es) 2016-10-05 2017-09-28 Compuestos de briostatina y metodos para prepararlos.

Country Status (11)

Country Link
US (3) US10947221B2 (es)
EP (1) EP3523296A4 (es)
JP (2) JP7148147B2 (es)
CN (1) CN109923110A (es)
AU (1) AU2017339786B2 (es)
CA (1) CA3038532A1 (es)
IL (2) IL265663B (es)
MX (1) MX2019003888A (es)
TW (1) TWI754676B (es)
WO (1) WO2018067382A1 (es)
ZA (1) ZA201902089B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067382A1 (en) 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
EP3972585A4 (en) * 2019-05-21 2023-06-21 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy
CN112209812B (zh) * 2019-07-11 2021-12-07 中国科学院大连化学物理研究所 一种1,1-二芳基-2-烷基乙烯衍生物及其合成方法
WO2022036335A1 (en) * 2020-08-09 2022-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Organ transplant perfusion solution modifications using bryostatin-1
MX2023005491A (es) 2020-11-24 2023-08-09 Lyell Immunopharma Inc Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716968A (en) * 1986-06-11 1998-02-10 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. H.
US5358711A (en) 1987-11-23 1994-10-25 Johns Hopkins University Stimulation of stem cell growth by the bryostatins
US5440055A (en) 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
CN1062866C (zh) * 1997-10-31 2001-03-07 中国人民解放军第二军医大学药学院 一种新的抗癌活性化合物草苔虫内酯
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2001040214A1 (en) * 1999-11-30 2001-06-07 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2003093275A1 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill A bryostatin composition
US8497385B2 (en) * 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US20100280262A1 (en) 2007-10-19 2010-11-04 Wender Paul A Bryostatin analogues, synthetic methods and uses
EP2283023A2 (en) 2008-04-16 2011-02-16 University of Utah Research Foundation Bryostatin analogues and methods of making and using thereof
US8816122B2 (en) * 2009-07-20 2014-08-26 The Board Of Trustees Of The Leland Stanford Junior University Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
CA2856235A1 (en) * 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla for the treatment of neurodegenerative disorders
WO2013162757A1 (en) * 2012-04-26 2013-10-31 Yale University Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
AU2015216875B2 (en) 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2016025363A1 (en) * 2014-08-11 2016-02-18 University Of Utah Research Foundation Bryostatin analogs and use thereof as antiviral agents
WO2018067382A1 (en) * 2016-10-05 2018-04-12 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds and methods of preparing the same
BR112019020203A2 (pt) 2017-03-31 2020-06-02 Cellectis Sa Células imunes universais modificadas do receptor de anticorpos quiméricos anti-cd22
AU2019301675B2 (en) 2018-07-12 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
EP3972585A4 (en) * 2019-05-21 2023-06-21 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin compounds for enhancement of immunotherapy

Also Published As

Publication number Publication date
TWI754676B (zh) 2022-02-11
WO2018067382A1 (en) 2018-04-12
CA3038532A1 (en) 2018-04-12
IL287119A (en) 2021-12-01
US11746105B2 (en) 2023-09-05
TW201815795A (zh) 2018-05-01
JP2022107010A (ja) 2022-07-20
US10947221B2 (en) 2021-03-16
IL287119B1 (en) 2023-03-01
US20190292172A1 (en) 2019-09-26
ZA201902089B (en) 2020-10-28
AU2017339786A1 (en) 2019-05-02
US20240116908A1 (en) 2024-04-11
IL265663A (en) 2019-05-30
EP3523296A4 (en) 2020-04-01
CN109923110A (zh) 2019-06-21
US12435071B2 (en) 2025-10-07
AU2017339786B2 (en) 2021-09-02
IL265663B (en) 2021-10-31
JP7148147B2 (ja) 2022-10-05
IL287119B2 (en) 2023-07-01
EP3523296A1 (en) 2019-08-14
US20210292309A1 (en) 2021-09-23
JP2019531295A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2019003888A (es) Compuestos de briostatina y metodos para prepararlos.
CO2018008707A2 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
MX2020006964A (es) Composicion farmaceutica que comprende un cannabinoide.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
MX387108B (es) Composición de cemento novedosa para una aplicación de pérdida de circulación.
MX2021012273A (es) Metodos y composiciones relacionadas con nanoportadores sinteticos con rapamicina en un estado estable, super-saturado.
CO2018001016A2 (es) Método de preparación de tereftalato de polietileno reforzado con grafeno mediante moldeo por inyección
CO6541621A2 (es) Anticuerpos que se unen preferencialmente al dominio 4 extracelular de csf 1r humano y uso de los mismos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
TN2016000478A1 (fr) Particules inorganiques individualisées.
UY35293A (es) Isotiazoles sustituidos con amino
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
AR100775A1 (es) Compuestos pesticidas y procedimientos relacionados con los mismos
CR20150588A (es) Métodos y composiciones para matriz de polímero sintetizada por policondensación
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
MX2015016300A (es) Polvos saborizantes chapados.
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
MX2016006591A (es) Agentes anticancerosos y sus preparaciones.
CO2018007112A2 (es) Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina
CO2017005983A2 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
CL2019000471A1 (es) Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448)